Health ❯ Healthcare ❯ Medicine

Oncology

Chronic Lymphocytic Leukemia Lung Cancer Breast Cancer Glioblastoma Acute Myeloid Leukemia Clinical Trials Multiple Myeloma Cancer Biology Cancer Treatment Chemotherapy Gastroesophageal Cancer Hepatocellular Carcinoma Meningioma Neuro-oncology Progression-Free Survival Lymphoma Mastocytosis Non-Small Cell Lung Cancer Radiation Therapy Personalized Medicine Targeted Therapy Hematology Biomarkers Leukemia

Oncolytic Viruses Trigger T‑Cell Infiltration and Survival Signals in Early Glioblastoma Trials

New reports highlight blood biomarkers to flag likely responders, with interferon gamma linked to the longest survivors in early testing.

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer